Find Clinical Trial

A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with bisphosphonates


← Back
Study Phase

Phase 3

Therapeutic Area

Rheumatology

IndicationOsteoporosis
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

STRONTIUM RANELATE,
S012911

Active Substance CodeS012911
Protocol CodeCL3-12911-038
EudraCT Code2011-000708-17


Documents and links

Results summary READ MORE




Quote

"A 24months, prospective, randomised, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate vs.placebo on BMD in postmenopausal osteoporotic women previously treated with bisphosphonates. D. Felsenberg, R. Chapurlat, R. Rizzoli, J.-Y. Reginster, P. Belissa- Mathiot. Osteoporosis International, Volume 29, Supplement 1, April 2018 Presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2018, April 19-22, 2018, Krakow, Poland Abstract No. P426"




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility